Twelve-month outcomes after coronary stenting with the genous™ bio-engineered R stent™ in diabetic patients from the e-HEALING registry

Journal of Interventional Cardiology

Volumn 24, Issue 4, 2011, Pages 285-294

  Damman, Peter ^a   Klomp, Margo ^a   Beijk, Marcel A ^a   Silber, Sigmund ^b   Grisold, Manfred ^c   Ribeiro, Expedito E ^d   Suryapranata, Harry ^e   Wãjcik, Jaroslaw ^f   Sim, Kui Hian ^g   Tijssen, Jan Gp ^a   De Winter, Robbert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Kardiologische Praxis und Praxisklinik   (Germany)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL DE WEEZENLANDEN   (Netherlands)

^f MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^g SARAWAK GENERAL HOSPITAL   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY STENT; DIABETIC PATIENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGISTER; STENT THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROSPECTIVE STUDIES; REGISTRIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 80051544549     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2010.00624.x     Document Type: Article

References (26)

1. West NE, Ruygrok PN, Disco CM, et al,. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109 (7): 867-873. (Pubitemid 38252739)
2. Kornowski R, Mintz GS, Kent KM, et al,. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997; 95 (6): 1366-1369. (Pubitemid 27142791)
3. Kirtane AJ, Gupta A, Iyengar S, et al,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119 (25): 3198-3206.
4. Stenestrand U, James SK, Lindback J, et al,. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: Long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010; 31 (2): 177-186.
5. Wenaweser P, Daemen J, Zwahlen M, et al,. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52 (14): 1134-1140.
6. van Werkum JW, Heestermans AA, Zomer AC, et al,. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53 (16): 1399-1409.
7. Silber S, Damman P, Klomp M, et al,. Clinical results after coronary stenting with the Genous™ Bio-engineered R stent™: 12-month outcomes of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry. EuroIntervention. February 2011. Accepted.
8. Cutlip DE, Windecker S, Mehran R, et al,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115 (17): 2344-2351. (Pubitemid 46685903)
9. Silber S, Albertsson P, Aviles FF, et al,. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26 (8): 804-847.
10. Lasala JM, Cox DA, Morris DL, et al,. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. Am J Cardiol 2009; 103 (12): 1663-1671.
11. Weber FD, Schneider H, Wiemer M, et al,. Sirolimus eluting stent (Cypher) in patients with diabetes mellitus: Results from the German Cypher Stent Registry. Clin Res Cardiol 2008; 97 (2): 105-109. (Pubitemid 351257994)
12. Kuchulakanti PK, Chu WW, Torguson R, et al,. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006; 98 (2): 187-192. (Pubitemid 43975495)
13. Garg P, Normand SL, Silbaugh TS, et al,. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation 2008; 118 (22): 2277-2285.
14. Novack V, Tsyvine D, Cohen DJ, et al,. Multivessel drug-eluting stenting and impact of diabetes mellitus-A report from the EVENT registry. Catheter Cardiovasc Interv 2009; 73 (7): 874-880.
15. Mahmud E, Ormiston JA, Turco MA, et al,. TAXUS Liberte attenuates the risk of restenosis in patients with medically treated diabetes mellitus: Results from the TAXUS ATLAS program. JACC Cardiovasc Interv 2009; 2 (3): 240-252.
16. Frobert O, Lagerqvist B, Carlsson J, et al,. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: A report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53 (18): 1660-1667.
17. Moussa I, Leon MB, Baim DS, et al,. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109 (19): 2273-2278. (Pubitemid 38678518)
18. Seabra-Gomes R,. Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart 2006; 92 (3): 410-419.
19. Buch AN, Javaid A, Steinberg DH, et al,. Outcomes after sirolimus-and paclitaxel-eluting stent implantation in patients with insulin-treated diabetes mellitus. Am J Cardiol 2008; 101 (9): 1253-1258.
20. Urban P, Gershlick AH, Guagliumi G, et al,. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006; 113 (11): 1434-1441. (Pubitemid 43739440)
21. Lotan C, Meredith IT, Mauri L, et al,. Safety and effectiveness of the endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009; 2 (12): 1227-1235.
22. Lasala JM, Cox DA, Dobies D, et al,. Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. Catheter Cardiovasc Interv 2008; 72 (4): 433-445.
23. Mulukutla SR, Vlachos HA, Marroquin OC, et al,. Impact of drug-eluting stents among insulin-treated diabetic patients: A report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008; 1 (2): 139-147. (Pubitemid 351506563)
24. Hill JM, Zalos G, Halcox JP, et al,. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348 (7): 593-5600.
25. Vasa M, Fichtlscherer S, Adler K, et al,. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103 (24): 2885-2890. (Pubitemid 32578123)
26. Garg S, Serruys PW,. Coronary stents: Current status. J Am Coll Cardiol 2010; 56 (10 Suppl): S1-S42.